Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing
Portfolio Pulse from
Medtronic reported Q2 earnings with a 5% revenue increase to $8.4bn and an adjusted EPS of $1.26. Despite consistent growth and new product launches, the share price remains flat due to unpredictable net income and modest innovation. CEO Geoff Martha highlighted strong performance in diabetes and hypertension but did not provide long-term growth guidance.
November 19, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Medtronic's Q2 earnings report shows revenue growth and a stable dividend, but the share price remains flat due to unpredictable net income and modest innovation. The CEO highlighted strong performance in key areas but did not provide long-term guidance.
Medtronic's revenue growth and stable dividend are positive, but the lack of long-term guidance and unpredictable net income keep the stock price flat. The market is likely to remain neutral until more clarity on future growth is provided.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100